MEFLOQUINE TABLET

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

MEFLOQUINE (MEFLOQUINE HYDROCHLORIDE)

Beschikbaar vanaf:

AA PHARMA INC

ATC-code:

P01BC02

INN (Algemene Internationale Benaming):

MEFLOQUINE

Dosering:

250MG

farmaceutische vorm:

TABLET

Samenstelling:

MEFLOQUINE (MEFLOQUINE HYDROCHLORIDE) 250MG

Toedieningsweg:

ORAL

Eenheden in pakket:

8

Prescription-type:

Prescription

Therapeutisch gebied:

ANTIMALARIALS

Product samenvatting:

Active ingredient group (AIG) number: 0124227001; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2010-05-26

Productkenmerken

_Product Monograph MEFLOQUINE _
_ _
_Page 1 of 39_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
MEFLOQUINE
Mefloquine Tablets
250 mg Mefloquine (as Mefloquine Hydrochloride)
ANTIMALARIAL AGENT
AA Pharma Inc.
1165 Creditstone Road, Unit#1
Vaughan, Ontario
L4K 4N7
Date of Revision:
September 20, 2017
Submission Control No: 206824
_ _
_Product Monograph MEFLOQUINE _
_Page 2 of 39 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................17
STORAGE AND STABILITY
..........................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................18
PART II: SCIENTIFIC INFORMATION
...............................................................................18
PHARMACEUTICAL INFORMATION
..........................................................................19
CLINICAL TRIALS
............................................................................................